[3-[[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxymethyl]oxetan-3-yl]methanamine | 1426928-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: [3-[[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxymethyl]oxetan-3-yl]methanamine
• 英文别名: [3-[[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxymethyl]oxetan-3-yl]methanamine
• CAS: 1426928-54-2
• 化学式: C₁₉H₁₈N₄O₃
• 分子量: 350.377
• InChiKey: WDALVSDVINPZBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  87.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-溴-6-氯咪唑并[1,2-b]哒嗪 在 四(三苯基膦)钯 、 sodium hydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 mineral oil 为溶剂， 反应 96.25h， 生成 [3-[[3-(1-Benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxymethyl]oxetan-3-yl]methanamine
  参考文献：
  名称：

  [EN] AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES
  [FR] IMIDAZOPYRIDAZINES AMINO-SUBSTITUÉES

  摘要：

  本发明涉及一般式(I)的氨基取代咪唑吡啶化合物，其中A、R1、R3和n如权利要求中所定义，以及制备所述化合物的方法，包括含有所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分结合。

  公开号：

  WO2013034570A1

文献信息

• AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES
  申请人：EIS Knut

  公开号：US20140296231A1

  公开（公告）日：2014-10-02

  The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R3 and n are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式（I）的氨基取代咪唑吡啶嗪化合物，其中A、R1、R3和n如权利要求中所定义，以制备上述化合物的方法，包括含有该化合物的制药组合物和药物组合物的制造用于治疗或预防疾病，特别是治疗或预防增生和/或血管生成障碍的制药组合物，作为唯一的药物或与其他活性成分联合使用。
• Organic Electroluminescence Element
  申请人：Takaku Koji

  公开号：US20140299851A1

  公开（公告）日：2014-10-09

  An organic electroluminescence element that uses a compound expressed by the following general formula has low inter-molecular interaction and high orientation during vapor deposition, and by using compounds that are resistant to aggregation, luminous efficiency is high, and there is little change in chromaticity accompanying drive deterioration (either V 1 or W 1 and either V 2 or W 2 form rings, the rings formed by V 1 and V 2 are six-membered rings, and the rings formed by W 1 and W 2 are five-membered rings; A 2 to A 4 and A 6 to A 8 represent CR Z or N, and R Z represents a hydrogen atom or a substituent; and R 2 , R 3 , R 7 , and R 8 represent a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a fluorine atom, a hydrogen atom [sic], or a deuterium atom.).
• US9499547B2
  申请人：——

  公开号：US9499547B2

  公开（公告）日：2016-11-22
• [EN] COMBINATION OF MKNK1-INHIBITORS<br/>[FR] COMBINAISON D'INHIBITEURS DE MKNK1
  申请人：BAYER PHARMA AG

  公开号：WO2017157418A1

  公开（公告）日：2017-09-21

  The present invention relates to combinations of at least two components, component A and component B, component A being a MKNK1-inhibitor of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a pharmaceutically acceptable salt, or a mixture of same, and component B being an anti-hyperproliferative, cytotoxic and/or cytostatic agent selected from a taxane, such as docetaxel or paclitaxel, or combinations thereof, and pemetrexed. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment of cancer and/or metastases thereof.
• [EN] AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES<br/>[FR] IMIDAZOPYRIDAZINES AMINO-SUBSTITUÉES
  申请人：BAYER IP GMBH

  公开号：WO2013034570A1

  公开（公告）日：2013-03-14

  The present invention relates to amino-substituted imidazopyridazine compounds of general formula(I): in which A, R1, R3 and n are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)的氨基取代咪唑吡啶化合物，其中A、R1、R3和n如权利要求中所定义，以及制备所述化合物的方法，包括含有所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分结合。